The Academy of Oncology Nurse Navigators white paper, "Assessing the Creative Application and Usefulness of NSider: A Tactical Tool for the Oncology Nurse Navigator" was published in the journal, The Oncology Nurse-APN/NP.

New study explains evolution of duplicate genesMedical XpressFrom time to time, living cells will accidently make an extra copy of a gene during the normal replication process. Throughout the history of life, evolution has molded some of these seemingly superfluous genes into a source of genetic novelty, adaptation and diversity.

Roche will work with Oryzon on cancer-suppressing genesBloombergRoche Holding AG agreed to buy the rights from Spain's Oryzon Genomics SA to an experimental drug that's meant to switch on genes that block the growth of cancer, a new area in the crowded field of potential oncology therapies. Roche will pay Barcelona-based Oryzon $21 million up front and for meeting near-term targets, plus payments that may exceed $500 million if the drug meets other goals.

Procrastination is in your genesTIMEEverybody has put off today what can be done tomorrow. And that might be because procrastination is in your genes, a new study published in the journal Psychological Science suggests. But when it comes to delaying, not everyone is created equal. Some are significantly more likely to procrastinate than others, so researchers at the University of Colorado Boulder looked into whether this bad habit might have its roots in genetics by surveying 181 identical twin pairs and 166 fraternal twin pairs.

Personalized medicine on a wearable patchEngineering.comImagine treating a debilitating illness simply by slapping on an electronic patch and forgetting that your condition even exists. While that future may seem fantastical and far-fetched, it could become a reality in the very near future. According to a paper published in Nature Nanotechnology, Korean researchers have developed a prototype patch that can measure muscle movement, administer medicine and keep a log of everything it has recorded.

Simple blood test might be enough to diagnose most forms of 'solid' cancer, with personalized medicineMedical DailyWhat if all forms of cancer could be detected by a simple blood test performed yearly in your doctor's office? Personalized medicine, which uses information from a person's genome to diagnose disease and select the most effective treatments, may soon make that possible. Researchers at Stanford's School of Medicine have developed a new personalized method for detecting disease by monitoring levels of cancerous DNA circulating in the blood.

Ears, noses grown from stem cells in lab dishesThe Associated Press via CBS NewsIn a north London hospital, scientists are growing noses, ears and blood vessels in the laboratory in a bold attempt to make body parts using stem cells. It is among several labs around the world, including in the U.S., that are working on the futuristic idea of growing custom-made organs in the lab.

Stem cells show promise for stroke recoveryHealthDay News via WebMDIn an early test, researchers report they've safely injected stem cells into the brains of 18 patients who had suffered strokes. And two of the patients showed significant improvement. All the patients saw some improvement in weakness or paralysis within six months of their procedures. Although three people developed complications related to the surgery, they all recovered. There were no adverse reactions to the transplanted stem cells themselves, the study authors said.

Stem cell researchers just figured out how to create new embryosGizmodoA team of researchers from the University of Virginia just made scientific history: They figured out how to turn stem cells into full blown fish embryos. In other words, scientists can now control embryonic development, a key to being able to grow organs and even entire organism from stem cells. "We have generated an animal by just instructing embryonic cells the right way," said Chris Thisse, who made the discovery with her husband Bernard. She added, "If we know how to instruct embryonic cells, we can pretty much do what we want."

Google Glass gets wearable neuro appHealthcare IT NewsIn a development that could help providers with remote patient monitoring and other telehealth applications, one developer has created a neuroimaging app designed to work with Google Glass. Created by Personal Neuro Devices, a Canadian application developer staffed with neuroscientists and biochemical engineers, the technology, called Introspect: the PND Wearable, is designed to enable Google Glass to give neuro-feedback to clinicians and caregivers.

Even small medical advances can mean big jumps in billsThe New York TimesCatherine Hayley is saving up for an important purchase: an updated version of the tiny digital pump at her waist that delivers lifesaving insulin under her skin. Such devices, which tailor insulin dosing more precisely to the body’s needs, have transformed the lives of people with Type 1 diabetes like Hayley.

New study explains evolution of duplicate genesMedical XpressFrom time to time, living cells will accidently make an extra copy of a gene during the normal replication process. Throughout the history of life, evolution has molded some of these seemingly superfluous genes into a source of genetic novelty, adaptation and diversity.

Gene therapy's big comebackForbesElliott Sigal earned a reputation at Bristol-Myers Squibb as one of the drug industry's best research chiefs. His bets on risky technologies like cancer immunotherapy and new types of diabetes drugs helped Bristol turn from a laggard into a growth stock.

Legal or not, marijuana cannot be ignored by healthcare providersBy Denise A. Valenti Two states — Colorado and Washington — have approved cannabis for both recreational use and medical use, an additional 18 approve the use of cannabis for medical purposes and an another 13 states have legislation pending. Regardless of a healthcare professional's position on medicinal cannabis or interest in prescribing its use, providers are expected by patients and the public to have the background necessary to provide guidance regarding the use of cannabis. Obtaining an education about a substance that is restricted, controversial and has few human studies on its use can seem daunting.

Number of Americans without health insurance reaches new lowLos Angeles TimesThe share of Americans without health insurance has dropped to the lowest level since before President Barack Obama took office, according to a new national survey that provides more evidence the healthcare law is extending coverage to millions of the previously uninsured.
Just 14.7 percent of adults lacked coverage in the second half of March, down from 18 percent in the last quarter of 2013, the survey from Gallup found.

Exchange enrollment exceeds expectations, but too early to determine impactBy Pamela Lewis Dolan The Obama administration's last-ditch efforts to get people to sign up for insurance through the insurance exchanges paid off as the total enrollment numbers exceeded 7 million by the March 31 open enrollment deadline. The enrollment data surprised nearly everyone. Just weeks before the deadline, the Congressional Budget Office revised its estimate of new enrollees down to 6 million. But while proponents of the Affordable Care Act had reason to celebrate, there are still many unknowns that will determine the long-term success of the law.

Hand-held treatment for overdoses is approvedThe New York TimesFederal health regulators approved a drug overdose treatment device that experts say will provide a powerful lifesaving tool in the midst of a surging epidemic of prescription drug abuse. Similar to an EpiPen used to stop allergic reactions to bee stings, the easy-to-use injector — small enough to tuck into a pocket or a medicine cabinet — can be used by the relatives or friends of people who have overdosed.

MannKind says FDA delays decision on inhaled insulin treatmentReutersMannKind Corp said the U.S. Food and Drug Administration extended the review date of its inhaled insulin treatment by three months, sending the company's shares down as much as 22 percent before the bell. The news comes less than a week after an advisory panel to the FDA recommended approving the treatment, Afrezza, but said longer-term studies would be required to gauge the risk of lung cancer and other potential side effects.

This edition of the Genomics Biotech and Emerging Medical Technologies Institute eBrief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!